Shelley's Events’ Post

Dr. Joel Moskowitz, Director at the University of California, Berkeley Center for Family and Community Health, has called for the International Agency for Research on Cancer to move forward on priorities it set years ago by tasking a working group to review the carcinogenicity of radio frequency radiation. EHT has been calling for a re-evaluation of the burgeoning science on wireless radiation and health for more than a decade. We heartily endorse Dr. Moskowitz’s call for the IARC to convene a serious and fully independent examination of the evidence. The Advisory Group recommended that this review be conducted within the next five years and called it a "high priority." See pages 148-149 of the following report: International Agency for Research on Cancer (IARC). Report of the Advisory Group to Recommend Priorities for the IARC Monographs during 2020–2024. IARC, World Health Organization, 2019. https://lnkd.in/gYUgbmhi. See Dr. Moskowitz’s statement about the Advisory Group’s recommendations and the IARC's actions below. "Although it is October, 2023, the IARC has yet to convene a working group to conduct a new review of RFR carcinogenicity. Is IARC afraid to conduct an independent expert review of RFR because the recommendations of independent experts may conflict with the forthcoming recommendations from two systematic reviews (SR1 and SR2) that the WHO commissioned? The WHO reviews are heavily influenced by members of the ICNIRP who have a conflict of interest to preserve ICNIRP's weak RFR exposure limits."

👉 Barriers to access high-quality care in NENs in EU: Within the 21st Annual European Neuroendocrine Tumor Society e.V. (ENETS) Conference, a roundtable discussion on barriers to access high-quality care in NENs in the EU was held with some of the most prominent NEN medical experts, INCA leadership representative and the European Commission representative. ✔ Thus, a comprehensive map of the policy framework of NET care in the EU was visualized by integrating the perspectives of physicians, patients and politicians. 👉 INCA was represented by Mark McDonnell, Past President and Chair of NET Patient Network, Ireland. INCA was also involved in the development of the EU NEN Policy Recommendations, being represented by Catherine Bouvier Ellis, Past President and CEO of Neuroendocrine Cancer UK. Mark McDonnell pointed out that the prevalence of NETs is so high, it goes beyond the definition of rare. Prof. Caplin noted that in terms of prevalence NETs are in the top 15 cancers and have to be considered with a different strategy.  🔹 Mandatory referral and network support in clinical trials Introduction of mandatory patient referral to specialist centers and network support in clinical trials across EU shaped the consensus among medical experts, patients and politicians. So far, EU policy on cancer has not addressed NETs. These major issues – ensuring access to NET specialists, knowledge and care standard pathways united all perspectives in recommendations for further action. ✔ Mark McDonnell noted that we just need to make sure that all recommendations will be implemented and we need to go forward with ensuring referrals for patients and network support in research.  ✅ Read more: https://lnkd.in/dJjmceDT #LetsTalkAboutNETs #NeuroendocrineCancer 

Our latest international collaboration is published online, the study about cancer-associated VTE education and awareness among cancer patients. (The study objective was to evaluate VTE-related education, awareness, and unmet needs from the perspective of people living with cancer using a quantitative and qualitative approach. Among 2262 patients with cancer from 42 countries worldwide, 55.3% received no VTE education throughout their cancer journey, and an additional 8.2% at the time of VTE diagnosis only, leading to 63.5% receiving none or inappropriately delayed education. When education was delivered, only 67.8% received instructions to seek medical attention in case of VTE suspicion, and 36.9% reported scarce understanding. One third of participants (32.4%) felt psychologically distressed when becoming aware of the potential risks and implications connected with cancer-associated VTE. Most responders (78.8%) deemed VTE awareness highly relevant, but almost half expressed concerns on the quality of education received. While overall consistent, findings in selected survey domains appeared to numerically differ across age groups, ethnicity, continent of residence, educational level, metastatic status, and VTE history. Conclusions This study involving a large and diverse population of individuals living with cancer identifies important unmet needs in VTE-related education, awareness, and support across healthcare systems globally. These findings unveil multilevel opportunities to expedite patient-centered care in cancer-associated VTE prevention and management). #CANCER #VTE #Thrombosis #Center Farjah Algahtani (MD,MPH)

"The role of patient organizations in social education and shaping health policy is unquestionable. No health care system will function properly without active and a well-educated patient. We, clinicians, are very interested in increasing the competences of this environment, which is why the meetings we plan are in the form of workshops aimed at exchanging experiences and knowledge" – prof. Ph.D. n. med. Piotr Rutkowski, chairman of the Polish Oncological Society. On September 29, 2023, a series of meetings has started "About the future of oncology. Forum of patient organizations and clinical experts’’. The aim of the initiative implemented by the Polish Oncological Society is to exchange knowledge and experience, as well as a partnership dialogue between clinical experts and representatives of organizations gathering cancer patients. From September 2023 to January 2024 Four educational meetings have been planned as part of the series, which will take place in September 2023 and January 2024. The first meeting entitled "Clinical guidelines in oncology - whether and how they work in Poland" was held on Friday, September 29, 2023 in Warsaw, at the National Institute of Oncology. Maria Skłodowska-Curie – National Research Institute (Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy) at 5 Roentgen Street. During the meeting, experts discussed, among others, the types of guidelines in Poland and the status of their implementation into clinical practice. The National Comprehensive Cancer Network® (NCCN®) guidelines were also discussed and the effects of the "One Voice, One Direction" project were presented. Representatives of the organization had the opportunity to share best practices in the education of oncology patients, which will then be collected in one publication and published at the end of the series. Link to the meeting entitled: "Clinical guidelines in oncology - whether and how they work in Poland": https://lnkd.in/dxydmCsT.

🔬 Seven research leaders from across La Trobe will share in more than $11.5 million in National Health and Medical Research Council (NHMRC) funding to bolster projects focused on fighting cancer and infectious disease, cancer rehabilitation, novel immunotherapies, viruses, and knee pain in young adults. The NHMRC Investigator Grants are highly competitive, rewarding only 229 of Australia’s top-performing researchers with a generous support package over a five-years period. Notable mentions include: ✨ $2.5m to Professor Stephanie Gras for her promising research into T-cell activation ✨ $2.7m to Assoc. Professor Dr Ivan Poon for his investigations into cell death, and the how this process plays out during viral infections and inflammatory diseases ✨ $2.9m to Professor Matthias Ernst for his vital investigations into how to improve patient responses to anti-cancer therapies 'The quality of research being undertaken at La Trobe is of the highest standard and the work being done in the area of #health and medical research is world-leading – this latest funding success underscores this,' said Senior Deputy Vice-Chancellor (Research & Industry Engagement) Professor Susan Dodds. Congratulations to all the talented scholars who were successful in this year's funding round 🩺🔬🦠 https://lnkd.in/gpFmhmDs #latrobeuni #medicalresearch #cancerresearch #immunology

Do you know what happened on this day 250 years ago?   In 1774, a ship’s surgeon in the British Royal Navy, James Lind, began what is widely considered to be the first randomised clinical trial. Since 2012, the total number of clinical trials starting every year in the UK averages at 631.   Core to our mission is helping patients prevail over serious diseases. This requires deep scientific expertise alongside cutting-edge capabilities and discovery platforms. Our clinical trials span several therapy areas, including: ◾ Oncology ◾ Cardiovascular diseases ◾ Haematology ◾ Immunology ◾ Neuroscience   Learn more about our clinical trial processes in the UK 👉 https://lnkd.in/eT7iJiBf   #BMSUK #ClinicalTrials #ClinicalTrialsDay

🌟 BCU: Dive into the forefront of innovations shaping the future of breast cancer! 🌐 We caught up with Prof. Willie VONGU, the 2024 BCU Co-President, to shed light on why every physician engaged in breast cancer should consider attending this conference, with a special focus on multidisciplinary approaches for a better care. It's not merely about networking or gaining practical insights applicable to your daily practice. Nor is it solely about updating your knowledge in treatment personalization or comprehending how AI and other innovations can enhance tailoring therapies to individual patient profiles. It goes beyond that, and as you'll soon discover, it's refreshingly straightforward! 🚀 Listen up! 🎙️ Oh, and here's an exciting update—The Breast Cancer Update conference has just received accreditation from the EACCME (European Accreditation Council for Continuing Medical Education) for a maximum of 18 European CME Credits (1) 🌟 Yet another compelling reason to be part of this enlightening experience. So, without a doubt, we eagerly anticipate meeting you in Dubai.  Save the date! 🗓️ February 2nd to 4th  Registration opens on https://jfim.org Prof. Willy Vangu, is Chief Specialist and Head of Nuclear Medicine at the University of the Witwatersrand for Charlotte Maxeke Johannesburg Academic Hospital and Chris Hani Baragwanath Academic Hospital. Additionally, he leads the department for Radiation Sciences at the University of the Witwatersrand. Holding an impressive array of academic qualifications, including MD, MMed, MSc, and Ph.D., he boasts a substantial portfolio of publications, conferences, workshop proceedings, and keynote addresses on both local and international platforms.   (1) Through an agreement between the EUMS (Union Européenne des Médecins Spécialistes) and the AMA (American Medical Association), physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found on ama-assn (American Medical Association) website. #BCUConference #BreastCancerAwareness #MedicalInnovation

𝗘𝗰𝗼𝗻𝗼𝗺𝗶𝗰 𝗮𝗻𝗮𝗹𝘆𝘀𝗲𝘀 𝗼𝗳 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝘀𝘂𝗽𝗽𝗼𝗿𝘁 𝘁𝗼𝗼𝗹𝘀 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗲𝗮𝗿𝗹𝘆 𝗱𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗰𝗮𝗻𝗰𝗲𝗿 The overall aim of this doctoral research is to develop a body of work in the area of economics of UGI cancer diagnosis and management. This will involve using large UK healthcare databases (e.g. comprehensive health care, cancer registries, and death registration databases) to assess disease risks, care pathways, health outcomes, and healthcare resources and their variation across the UK population. Developing a decision-analytic health policy model of UGI cancer diagnosis and treatment to inform assessments of the long-term health outcomes and costs related to new UGI cancer diagnosis strategies is a further project aim. Funding Availability: This 4-year studentship is funded through a Cancer Research UK Programme Grant (CanDetect) with a tax-free stipend of £23,000. Funding for this project is available to UK citizens. LInk : https://lnkd.in/d6ZtKJa2

📢 Announced Today: First Ascent Biomedical Presents Findings from Clinical Studies in Pediatric and Adult Cancers Using its AI-Enhanced Functional Precision Medicine Platform at ASCO 2024 Exciting developments will be presented today at #ASCO2024, highlighting the potential for significant advancements in personalized treatment and health equity. Our recent studies suggest that #FPM data can now be reliably and swiftly generated even through minimally invasive small-needle biopsies. This offers a promising avenue for expanding access to validation of personalized treatment options. Concurrently, we presented research supported by the National Institute on Minority Health and Health Disparities (NIMHD) investigating the relationship between racial/ethnic background and response to cancer therapies, aiming to mitigate existing health inequalities and develop novel predictive biomarkers. These new findings underscore the efficacy of our FPM platform, particularly in cases where standard treatments prove ineffective, as demonstrated in Nature Medicine's April issue. We’re proud to collaborate with Florida International University, Cleveland Clinic Florida, Nicklaus Children's Hospital Foundation, Live Like Bella® Childhood Cancer Foundation, the Florida Department of Health/ Live Like Bella Pediatric Cancer Research Initiative, the National Institute of Minority Health Disparities (NIMHD), the Community Foundation of Broward, the Scott R. MacKenzie Foundation, and many others. These partnerships are instrumental in advancing our mission to ensure that the right drug reaches the right patient at the right time. Read our press release, or stop by from 9-12 at the Poster Session for Care Delivery/Models of Care and from 1:30 – 4:30 for the Pediatric Oncology Session to learn more: https://lnkd.in/gEYTxHzT #Oncology #CancerResearch #FunctionalPrecisionMedicine #AI #PersonalizedMedicine

MSD Global Oncology Policy Grant See our latest (24 January 2024) publication in ecancermedical science titled: Harnessing the law to advance equitable cancer care in South Africa: exploring the feasibility, desirability and added value of a dedicated national cancer act. Please access the article here: https://lnkd.in/dmF4MUKy Study Description: This is a collaborative research study with the Cancer Alliance, Cancer Association of South Africa, Global Health Unit, Institute of Cancer Policy, Kings College London and Department of Family Medicine and Primary Care, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand. The study explored whether a dedicated National Cancer Act in South Africa will provide the necessary long-term national goal-setting and accountability framework to link with other legal and human rights mechanisms, to ensure equitable population-based cancer healthcare services and appropriate patient protection. Funding for this study was received from the 2021 MSD Independent Oncology Policy Grant Program. #CANSAResearch